Sarepta Therapeutics Shares Surge on Analyst Optimism

Strong Financial Performance Underpins Rally

Sarepta Therapeutics witnessed a dramatic trading session as its stock price jumped more than 10%, closing at $21.32 before extending gains in after-hours activity. This powerful upward movement stems from recent analyst upgrades and continued momentum following the company’s impressive quarterly earnings report.

The biotechnology firm’s fundamental results provided a solid foundation for the market enthusiasm. Sarepta reported quarterly earnings of $2.02 per share, substantially exceeding analyst projections of $0.89. Revenue reached $611 million, surpassing estimates by $80 million and representing impressive year-over-year growth of 68.4%.

Wall Street Support Builds Momentum